Overview
October 5: Short Course
October 6-7: Forum
This year marks the 10th Anniversary of the Biosimilars Price Competition and Innovation Act (BPCIA), which created a biosimilars approval pathway in the US with the goal of increasing access to safe, effective, and cost effective biological treatment options for patients. To date, significant progress has been made in the science and regulation of biosimilar development and approval, and awareness and educational efforts are increasing prescriber and patient confidence and uptake. The challenges have been and continue to be complex, interrelated, and best addressed by stakeholder collaboration, not only within the US but across global regions.
To sustain the momentum, stakeholders are now looking forward – to streamlining biosimilars development, meeting ongoing manufacturing challenges as well as those posed by the COVID-19 pandemic, addressing pricing issues, and to discovering new targets for biosimilar development. At the DIA 2020 Biosimilars Conference, manufacturers, regulators, payers, prescribers, and patients will come together to envision the biosimilars landscape of the next 5 years and to share perspectives on what success and equilibrium will look like. They’ll apply the newest thinking and relevant learnings from global regions to build strategies for continuing the growth of the biosimilars market and bringing these important biologic therapies – and cost savings - to patients.
Program Now Available!
The program has been released! Preview all session descriptions, speakers, and more all in one place!
ViewProgram Committee
-
Hillel P Cohen, PhD Executive Director, Scientific Affairs
Sandoz Inc., United States -
Cecil J. Nick, MS FTOPRA, Vice President (Technical)
Parexel Consulting, United Kingdom -
Julie Marechal-Jamil, MSc Director, Biosimilar Policy and Science
Medicines For Europe, Belgium -
Jian Wang, MD, PhD Division Manager, Clinical Review Division – Heamatology/Oncology
Health Canada, Canada -
Leah Christl, PhD Exec Director, Global Biosimilars Regulatory Affairs & Regulatory & R&D Policy
Amgen, United States -
Laura McKinley, PhD Director, Global Regulatory Policy and Intelligence
Pfizer Inc, United States -
Sarah Yim, MD Director, Office of Therapeutic Biologics and Biosimilars, OND, CDER
FDA, United States -
Tiffany Fletcher, MA Head of Global Access Policy
Viatris, United States -
Anna Welch, MA Chief Editor, Biosimilar Development
Life Science Connect, United States -
Laura D. Wingate Executive Vice President, Education, Support, and Advocacy
Crohn's & Colitis Foundation, United States
Have an account?